Model structures of α-2 adrenoceptors in complex with automatically docked antagonist ligands raise the possibility of interactions dissimilar from agonist ligands

Journal of Structural Biology

Volumn 150, Issue 2, 2005, Pages 126-143

  Xhaard, Henri ^a   Nyrönen, Tommi ^b   Rantanen, Ville Veikko ^a,c   Ruuskanen, Jori O ^c   Laurila, Jonne ^c   Salminen, Tiina ^a   Scheinin, Mika ^c   Johnson, Mark S ^a  

^a ÅBO AKADEMI UNIVERSITY   (Finland)

^b IT Center for Science   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Antagonist ligand binding; G protein coupled receptors; Ligand docking; Receptor subtypes; Structure modeling; 2 adrenergic receptor

Indexed keywords

1,3,4,5',6,6',7,12B OCTAHYDRO 1',3' DIMETHYL 2H SPIRO[BENZO[B]FURO[2,3 A]QUINOLIZINE 2,4' PYRIMIDINE] 2' ONE; 1,4 BIS(1,4 BENZODIOXAN 2 YL METHYL)PIPERAZINE; 2 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 4,4 DIMETHYL 1,3(2H,4H) ISOQUINOLINEDIONE; 2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; 6 METHYL 8BETA [(2 PHENYL 1 IMIDAZOLYL)METHYL]ERGOLINE; ABANOQUIL; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DOXAZOSIN; PHENOXYBENZAMINE; PRAZOSIN; RECEPTOR SUBTYPE; SPIPERONE; SPIROXATRINE; UNCLASSIFIED DRUG; YOHIMBINE;

ARTICLE; ATOMIC PARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ELECTRICITY; LIGAND BINDING; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

BOVINAE;

EID: 18144409461     PISSN: 10478477     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsb.2004.12.008     Document Type: Article

References (55)

1. J.A. Ballesteros, and H. Weinstein Integrated methods for the construction of three dimensional models and computational probing of structure-function relationships in G-protein coupled receptors Methods Neurosci. 25 1995 366 428
2. R. Barbaro, L. Betti, M. Botta, F. Corelli, G. Giannaccini, L. Maccari, F. Manetti, G. Strappaghetti, and S. Corsano Synthesis and biological activity of new 1,4-benzodioxan-arylpiperazine derivatives. Further validation of a pharmacophore model for alpha(1)-adrenoceptor antagonists Bioorg. Med. Chem. 10 2002 361 369
3. P. Bar-On, C.B. Millard, M. Harel, H. Dvir, A. Enz, J.L. Sussman, and I. Silman Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine Biochemistry 41 2002 3555 3564
4. G.J. Barton ALSCRIPT: a tool to format multiple sequence alignments Protein Eng. 6 1993 37 40
5. C. Bissantz, P. Bernard, M. Hibert, and D. Rogan Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets? Proteins 50 2003 5 25
6. K. Bondensgaard, M. Ankersen, H. Thogersen, B.S. Hansen, B.S. Wulff, and R.P. Bywater Recognition of privilegied structures by G-protein coupled receptors J. Med. Chem. 47 2004 888 899
7. J.B. Bremner, B. Coban, R. Griffith, K.M. Groenewoud, and B.F. Yates Ligand design for alpha-1 adrenoceptor subtype selective antagonists Bioorg Med. Chem. Lett. 8 2000 201 214
8. B.L. de Groot, A. Engel, and H. Grubmuller The structure of the aquaporin-1 water channel: a comparison between cryo-electron microscopy and X-ray crystallography J. Mol. Biol. 325 2003 485 493
9. K. Denessiouk, and M.S. Johnson "Acceptor-donor-acceptor" motifs recognize the Watson-Crick, Hoogsteen and Sugar "donor-acceptor- donor" edges of adenine and adenosine-containing ligands J. Mol. Biol. 333 2003 1025 1043
10. M.D. Eldridge, C.W. Murray, T.R. Auton, G.V. Paolini, and R.P. Mee Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes J. Comput. Aided Mol. Des. 11 1997 425 445
11. H. Frang, V. Cockcroft, T. Karskela, M. Scheinin, and A. Marjamäki Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors J. Biol. Chem. 276 2001 31279 31284
12. U. Gether, S. Lin, P. Ghanouni, J.A. Ballesteros, H. Weinstein, and B.K. Kobilka Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor EMBO J. 16 1997 6737 6747
13. B.Y. Ho, A. Karschin, T. Branchek, N. Davidson, and H.A. Lester The role of conserved aspartate and serine residues in ligand binding and in function of the 5-HT1A receptor: a site-directed mutation study FEBS Lett. 312 1992 259 262
14. M. Ishiguro, Y. Futabayashi, T. Ohnuki, M. Ahmed, I. Muramatsu, and T. Nagatomo Identification of binding sites of prazosin, tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling Life Sci. 71 2002 2531 2541
15. M.S. Johnson, and J.P. Overington A structural basis for sequence comparisons. An evaluation of scoring methodologies J. Mol. Biol. 233 1993 716 738
16. G. Jones, P. Willett, R.C. Glen, A.R. Leach, and R. Taylor Development and Validation of a Genetic Algorithm for Flexible Docking J. Mol. Biol. 267 1997 727 748
17. P.J. Kraulis MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures J. Appl. Crystallogr. 24 1991 946 950
18. K. Kristiansen, W.K. Kroeze, D.L. Willins, E.I. Gelber, J.E. Savage, R.A. Glennon, and B.L. Roth A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism J. Pharmacol. Exp. Ther. 293 2000 735 746
19. G. Kryger, I. Silman, and J.L. Sussman Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs Struct. Fold Des. 7 1999 297 307
20. I.V. Kurinov, and R.W. Harrison Prediction of new serine proteinase inhibitors Nat. Struct. Biol. 1 1994 735 743
21. J.V. Lehtonen, D.J. Still, V.V. Rantanen, J. Ekholm, D. Björklund, Z. Iftikhar, M. Huhtala, S. Repo, A. Jussila, J. Jaakkola, O. Pentikäinen, T. Nyrönen, T. Salminen, M. Gyllenberg, and M.S. Johnson BODIL: a molecular modeling environment for structure-function analysis and drug design J. Comput. Aided Mol. Des. 18 2004 401 419
22. R. Link, D. Daunt, G. Barsh, A. Chruscinki, and B. Kobilka Cloning of two mouse genes encoding alpha 2-adrenergic receptor subtypes and identification of a single amino acid in the mouse alpha 2-C10 homolog responsible for an interspecies variation in antagonist binding Mol. Pharmacol. 42 1992 16 27
23. S.C. Lovell, J.M. Word, J.S. Richardson, and D.C. Richardson The penultimate rotamer library Proteins 40 2000 389 408
24. B.K. Madras, M.A. Fahey, G.M. Miller, R. De La Garza, M. Goulet, R.D. Spealman, P.C. Meltzer, S.R. George, B.F. O'Dowd, A.A. Bonab, E. Livni, and A.J. Fischman Non-amine-based dopamine transporter (reuptake) inhibitors retain properties of amine-based progenitors Eur. J. Pharmacol. 479 2003 41 51
25. A. Marjamäki, H. Frang, M. Pihlavisto, A.M. Hoffrén, T. Salminen, M.S. Johnson, J. Kallio, J.A. Javitch, and M. Scheinin Chloroethylclonidine and 2-aminoethyl methanethiosulfonate recognize two different conformations of the human alpha(2A)-adrenergic receptor J. Biol. Chem. 274 1999 21867 21872
26. F.M. McMillan, J. Archbold, M.J. McLeish, J.M. Caine, K.R. Criscione, G.L. Grunewald, and J.L. Martin Molecular recognition of sub-micromolar inhibitors by the epinephrine-synthesizing enzyme phenylethanolamine N-methyltransferase J. Med. Chem. 47 2004 37 44
27. E.A. Merritt, and D.J. Bacon Raster3D: photorealistic molecular graphics Methods Enzymol. 277 1997 505 524
28. T. Nickel, U. Bauer, E. Schlicker, M. Kathmann, M. Gothert, A. Sasse, H. Stark, and W. Schunack Novel histamine H(3)-receptor antagonists and partial agonists with a non-aminergic structure Br. J. Pharmacol. 132 2001 1665 1672
29. T. Nyrönen, M. Pihlavisto, J.M. Peltonen, A.M. Hoffrén, M. Varis, T. Salminen, S. Wurster, A. Marjamäki, L. Kanerva, E. Katainen, L. Laaksonen, J.M. Savola, M. Scheinin, and M.S. Johnson Molecular mechanism for agonist-promoted alpha(2A)-adrenoceptor activation by norepinephrine and epinephrine Mol. Pharmacol. 59 2001 1343 1354
30. T. Okada, Y. Fujiyoshi, M. Silow, J. Navarro, E.M. Landau, and Y. Shichida Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography Proc. Natl. Acad. Sci. USA 99 2002 5982 5987
31. K. Palczewski, T. Kumasaka, T. Hori, C.A. Behnke, H. Motoshima, B.A. Fox, I.L. Trong, D.C. Teller, T. Okada, R.E. Stenkamp, M. Yamamoto, and M. Miyano Crystal structure of rhodopsin: a G-coupled protein receptor Science 289 2000 739 745
32. J.M. Peltonen, T. Nyrönen, S. Wurster, M. Pihlavisto, A.M. Hoffrén, A. Marjamäki, H. Xhaard, L. Kanerva, J.M. Savola, M.S. Johnson, and M. Scheinin Molecular mechanisms of ligand-receptor interactions in transmembrane domain V of the alpha2A-adrenoceptor Br. J. Pharmacol. 140 2003 347 358
33. J.E. Porter, J. Hwa, and D.M. Perez Activation of the alpha1b-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint J. Biol. Chem. 271 1996 28318 28323
34. V.V. Rantanen, K.A. Denessiouk, M. Gyllenberg, T. Koski, and M.S. Johnson A fragment library based on Gaussian mixtures predicting favorable molecular interactions J. Mol. Biol. 313 2001 197 214
35. V.V. Rantanen, M. Gyllenberg, T. Koski, and M.S. Johnson A Bayesian molecular interaction library J. Comput. Aided Mol. Des. 17 2003 435 461
36. J.W. Regan, T.S. Kobilka, T.L. Yang-Feng, M.G. Caron, R.J. Lefkowitz, and B.K. Kobilka Cloning and expression of a human kidney cDNA for an alpha2-adrenergic receptor subtype Proc. Natl. Acad. Sci. USA 85 1988 6301 6305
37. B.L. Roth, K. Baner, R. Westkaemper, D. Siebert, K.C. Rice, S. Steinberg, P. Ernsberger, and R.B. Rothman Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist Proc. Natl. Acad. Sci. USA 99 2002 11934 11939
38. J.O. Ruuskanen, H. Xhaard, A. Marjamäki, E. Salaneck, T. Salminen, Y.L. Yan, J.H. Postlethwait, M.S. Johnson, D. Larhammar, and M. Scheinin Identification of duplicated fourth alpha2-adrenergic receptor subtype by cloning and mapping of five receptor genes in zebrafish Mol. Biol. Evol. 21 2004 14 28
39. J.O. Ruuskanen, J. Laurila, H. Xhaard, V.V. Rantanen, K. Vuoriluoto, S. Wurster, A. Marjamäki, M. Vainio, M.S. Johnson, and M. Scheinin Conserved structural, pharmacological and functional properties among the three human and five zebrafish alpha-2-adrenoceptors Br. J. Pharmacol. 144 2005 165 177
40. A. Pedretti, M.E. Silva, L. Villa, and G. Vistoli Binding site analysis of full-length alpha-1a adrenergic receptor using homology modeling and molecular docking Biochem. Biophys. Res. Commun. 319 2004 493 500
41. T. Salminen, M. Varis, T. Nyrönen, M. Pihlavisto, A.-M. Hoffrén, T. Lönnberg, A. Marjamäki, H. Frang, J.-M. Savola, M. Scheinin, and M.S. Johnson Three dimensional models of alpha 2-adrenergic receptor complexes provides a structural explanation for ligand binding J. Biol. Chem. 274 1999 23405 23413
42. A. Šali, and T.L. Blundell Comparative protein modelling by satisfaction of spatial restraints J. Mol. Biol. 234 1993 779 815
43. S. Shacham, Y. Marantz, S. Bar-Haim, O. Kalid, D. Warshaviak, N. Avisar, B. Inbal, A. Heifetz, M. Fichman, M. Topf, Z. Naor, S. Noiman, and O.M. Becker Modeling and in silico screening for G-protein coupled receptors Proteins. 57 2004 51 86
44. M.A. Schumacher, M.C. Miller, S. Grkovic, M.H. Brown, R.A. Skurray, and R.G. Brennan Structural mechanisms of QacR induction and multidrug recognition Science 294 2001 2158 2163
45. L. Shi, and J.A. Javitch The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop Annu. Rev. Pharmacol. Toxicol. 42 2002 437 467
46. L. Shi, and J.A. Javitch The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice Proc. Natl. Acad. Sci. USA 101 2004 440 445
47. S. Suryanarayana, D.A. Daunt, M. von Zastrow, and B.K. Kobilka A point mutation in the seventh hydrophobic domain of the alpha 2 adrenergic receptor increases its affinity for a family of beta receptor antagonists J. Biol. Chem. 266 1991 15488 15492
48. D.C. Teller, T. Okada, C.A. Behnke, K. Palczewski, and R.E. Stenkamp Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs) Biochemistry 40 2001 7761 7772
49. S. Uhlén, M. Dambrova, J. Nasmän, H.B. Schiöth, Y. Gu, A. Wikberg-Matsson, and J.E. Wikberg [3H]RS79948-197 binding to human, rat, guinea pig and pig alpha2A-, alpha2B- and alpha2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine Eur. J. Pharmacol. 343 1998 93 101
50. E. Vardy, I.T. Arkin, K.E. Gottschalk, H.R. Kaback, and S. Schuldiner Structural conservation in the major facilitator superfamily as revealed by comparative modeling Protein Sci. 13 2004 1832 1840
51. V. Venkataraman, T. Duda, and R.K. Sharma A role for amino acid residues in the third cytoplasmic loop in defining the ligand binding characteristics of the alpha2D-adrenergic receptor Mol. Cell Biochem. 177 1997 125 129 Erratum in: 1998 Mol. Cell Biochem., 183, 221
52. C.-D. Wang, M.A. Buck, and C.M. Fraser Site-directed mutagenesis of alpha 2a-adrenergic receptors: Identification of amino acids involved in ligand binding and receptor activation by agonists Mol. Pharmacol. 40 1991 168 179
53. T. Wurch, F.C. Colpaert, and P.J. Pauwels Chimeric receptor analysis of the ketanserin binding site in the human 5-hydroxytryptamine 1D receptor: importance of the second extracellular loop and fifth transmembrane domain in antagonist Binding Mol. Pharmacol. 54 1998 1088 1096
54. N. Zacharias, and D.A. Dougherty Cation-pi interactions in ligand recognition and catalysis Trends Pharmacol. Sci. 23 2002 281 287
55. M.M. Zhao, J. Hwa, and D.M. Perez Identification of critical extracellular loop residues involved in alpha1-adrenergic receptor subtype-selective antagonist binding Mol. Pharmacol. 50 1996 1118 1126